Fluidigm supports the response to the global COVID-19 pandemic with technologies that enable research and applications for SARS-CoV-2 virus detection and the monitoring of human immune system response to infection and COVID-19 disease. To that end, our technologies are well-positioned for use in providing a robust public research response in support of policies and treatments aligned with local, state and national recovery.
Fluidigm RNA detection products, Biomark™ HD and integrated fluidic circuit (IFC) technologies can be used to develop high-throughput, scalable and cost-effective SARS-CoV-2 detection in public, private and government testing environments. A single installed platform can test 6,000 samples in 24 hours using established CDC and WHO methods with lower reagent requirements than comparable systems.
Fluidigm CyTOF® technology with the Maxpar® Direct™ Immune Profiling Assay™ provide best-in-class immune monitoring with the cost, flexibility and consistency needed for standardized COVID-19 disease immune monitoring research. Imaging Mass Cytometry™ adds the capability of spatial visualization of immune response in tissue samples. This newly developed technology enables the study of clinical outcomes and changes in inflammatory or immune function directly from whole blood samples or tissues.
Both CyTOF technology with the Maxpar Direct Immune Profiling Assay and Imaging Mass Cytometry enable immune response studies designed to identify prognostic and mechanistic biomarkers that can be used to guide the development of effective vaccines and guide treatment of COVID-19 patients. Understanding immune response and disease immunopathology can help refine development of treatments and vaccines for better disease management.
Learn more about the Maxpar® Direct™ Immune Profiling Assay™ and Maxpar Pathsetter™ software, the first complete sample-to-answer solution for high-dimensional immune profiling of human PBMC and whole blood. Proven performance in multi-site studies.
Read the recent paper from University of Paris researchers to see how this immune profiling assay has been used to define a distinct immune response phenotype in severe and critically ill COVID-19 patients that could help identify high-risk individuals.
- Publication : Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients | Hadjadj, J. et al. medRxiv (2020): doi:10.1101/2020.04.19.20068015.
- Infographic Poster: Maxpar Direct Immune Profiling Assay and Maxpar Pathsetter Software
- Flyer: Maxpar Direct Immune Profiling System
- Application Note: Cryopreservation of samples processed with the Maxpar Direct Immune Profiling Assay
- White Paper: Performance of the Maxpar Direct Immune Profiling System
Therapeutic Insights Services offers sample-to-answer mass cytometry and Imaging Mass Cytometry services for your research needs. If expertise and capabilities are needed for your COVID-19 related research or if local facilities are affected by closures, we are ready to assist. Consultation, sample staining and data acquisition and analysis options are available. Select services offered include:
- Custom panel design
- Data analysis and reporting
- Sample staining
- Mass cytometry data acquisition and analysis
- Imaging Mass Cytometry data acquisition, processing and analysis
Fluidigm Infectious Disease and Oncology Virtual Summit
We invite you to join us for a half-day virtual event where researchers will share their latest findings in infectious disease, oncology or immuno-oncology research. Speakers will include Burkhard Becher, PhD, Evan Newell, PhD, Hiroyoshi Nishikawa, MD, PhD, and Kurt Schalper, MD, PhD.
Don’t miss this exciting event bridging the space from technological innovations to real world applications and results that impact human health.
Bring the Power of CyTOF to COVID-19 Research Webinar
Andrew Quong, PhD
Chief Science Officer
Detection and Characterization of Viral Pathogens with Microfluidics-Based Genomic Analysis Webinar
Bill Hunt, MS
Director, Microfluidics Product Management